A new targeted alpha therapy is showing promise for patients whose thyroid cancer no longer responds to radioactive iodine, the standard beta-emitting treatment. In a first-in-human study, ...
Results of management of cervical lymph node metastases in differentiated thyroid carcinoma: Experience in an upper middle-income country. This is an ASCO Meeting Abstract from the 2025 ASCO Annual ...
Feasibility of 6 months of maintenance cetuximab after adjuvant concurrent chemoradiation plus cetuximab in squamous cell carcinoma of the head and neck (HNC). This is an ASCO Meeting Abstract from ...
A combination of pretherapy imaging and dosimetry can help ensure that patients with refractory differentiated thyroid cancer obtain the maximum benefit from radioactive iodine treatments following ...
Reston, VA (December 4, 2025)--A new targeted alpha therapy is showing promise for patients whose thyroid cancer no longer responds to radioactive iodine, the standard beta-emitting treatment. In a ...
Although survival rates are high, thyroid cancer patients often face unnecessary treatments due to the reliance on inaccurate ...
Please provide your email address to receive an email when new articles are posted on . Among a group of patients with differentiated thyroid cancer, 10-year disease-specific survival was 97.2%.
Lenvatinib, an oral inhibitor of vascular endothelial growth factor receptors 1, 2, and 3, fibroblast growth factor receptors 1 through 4, platelet-derived growth factor receptor α, RET, and KIT, ...
Please provide your email address to receive an email when new articles are posted on . Patients with primary thyroid cancer who received radioactive iodine therapy had elevated risk for melanoma/skin ...
Hosted on MSN
Skipping radioactive iodine after thyroid cancer surgery could mean more time with loved ones for low-risk patients
Radioactive iodine treatment after thyroid cancer surgery usually means side effects like nausea and time in hospital isolated from loved ones. But new clinical trial results from researchers at UCL ...
Vemurafenib (Zelboraf, Roche/Genentech), a BRAF inhibitor marketed for use in the treatment of melanoma, has now shown activity in patients with refractory papillary thyroid cancer. For the ...
June 6, 2007 (Chicago) — Pfizer's experimental drug axitinib may offer patients with advanced thyroid cancer who have not responded to previous therapies such as surgery and radioactive iodine a new ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results